Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C
Status:
Withdrawn
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This observational prospective registry is designed to evaluate the safety, adherence, and
efficacy of prescribed, patient-administered therapy with Infergen® (Interferon alfacon 1)
and other prescribed therapies in patients chronically infected with HCV. The primary
endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends.